Acute renal failure following intravenous administration of hepatitis B immunoglobulin in liver transplantation

Minerva Gastroenterologica e Dietologica

Volumn 55, Issue 4, 2009, Pages 501-504

  Donataccio, M ^a   Dalle Ore, G ^a   Donataccio, D ^a  

^a UNIVERSITY HOSPITAL OF VERONA   (Italy)

Author keywords

Drug toxicity; Immunoglobulins, intravenous; Kidney failure, acute; Liver transplantation

Indexed keywords

CALCINEURIN INHIBITOR; GANCICLOVIR; HEPATITIS B ANTIBODY;

ACUTE KIDNEY FAILURE; ADULT; ARTICLE; CASE REPORT; CYTOMEGALOVIRUS INFECTION; DIURESIS; HUMAN; KIDNEY FUNCTION; LIVER CIRRHOSIS; LIVER GRAFT REJECTION; LIVER TRANSPLANTATION;

ADULT; ANTIVIRAL AGENTS; CREATININE; FEMALE; GANCICLOVIR; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; KIDNEY FAILURE, ACUTE; LIVER CIRRHOSIS; LIVER TRANSPLANTATION; RISK FACTORS; TIME FACTORS;

EID: 77949500625     PISSN: 00264776     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (14)

1. Orbach H, Katz U, Sherer Y, Shoenfeld Y. Intravenous immunoglobulin: adverse effects and safe administration. Clin Rev Allergy Immunol 2005;29:173-84.
2. Chapman SA, Gilkerson KL, Davin TD, Pritzker MR. Acute renal failure and intravenous immune globulin: occurs with sucrose-stabilized, but not with D-sorbitol-stabilized, formulation. Ann Pharmacother 2004;38:2059-67.
3. Daphnis E, Stylianou K, Alexandrakis M, Xylouri I, Vardaki E, Stratigis S et al. Acute renal failure, translocational hyponatremia and hyperkalemia following intravenous immunoglobulin therapy. Nephron Clin Pract 2007;106:c143-8.
4. Carbone J. Adverse reactions and pathogen safety of intravenous immunoglobulin. Curr Drug Saf 2007;2:9-18.
5. Centers for Disease Control and Prevention (CDC). Renal insufficiency and failure associated with immune globulin intravenous therapy - United States, 1985-1998. MMWR Morb Mortal Wkly Rep 1999;48:518-21.
6. Levy JB, Pusey CD. Nephrotoxicity of intravenous immunoglobulin. QJM 2000;93:751-5.
7. Vo AA, Cam V, Toyoda M, Puliyanda DP, Lukovsky M, Bunnapradist S et al. Safety and adverse events profiles of intravenous gammaglobulin products used for immunomodulation: a single-center experience. Clin J Am Soc Nephrol 2006;1:844-52.
8. Lerut JP, Donataccio M, Ciccarelli O, Roggen F, Jamart J, Laterre PF et al. Liver transplantation and HBsAg-positive postnecrotic cirrhosis: adequate immunoprophylaxis and delta virus co-infection as the significant determinants of long-term prognosis. J Hepatol 1999;30:706-14.
9. Donataccio M, Ruzzenente A, Pachera S, Genco B, Donataccio D. Caval anastomosis in liver transplantation: prospective experience of Verona liver transplantation program. Transplant Proc 2005;37:2605-6.
10. Katz U, Achiron A, Sherer Y, Shoenfeld Y. Safety of intravenous immunoglobulin (IVIG) therapy. Autoimmun Rev 2007;6:257-9.
11. Soares SM, Sethi S. Impairment of renal function after intravenous immunoglobulin. Nephrol Dial Transplant 2006;21:816-7.
12. Angeli P, Scaglione F. Nephrotoxicity of intravenous immmunoglobulin in the setting of liver transplantation or HBV-related cirrhosis: an undervalued topic. Minerva Gastroenterol Dietol 2008;54:259-75.
13. Bismuth A, Arulnaden JL, Samuel D, David MF, Pichon F, Mathieu D et al. Prophylaxie des recidives chez les transplantès hèpatiques pour atteinte hèpatique due au virus de l'Hèpatite B. Rev Fr Transfus Hemobiol 1992;35:107-23.
14. Lerut JP, Molle G, Donataccio M, De Kock M, Ciccarelli O, Laterre PF et al. Cavocaval liver transplantation without venovenous bypass and without temporary portocaval shunting: the ideal technique for adult liver grafting? Transpl Int 1997;10:171-9.